For all of the groundbreaking advancements in cancer treatment over the last decades, the first step for tackling almost all solid tumors is still surgery. | For all of the groundbreaking advancements ...

Only a couple of months ago, Sensei Biotherapeutics was laying off staff and mulling winding down the company. | Only a couple of months ago, Sensei Biotherapeutics was laying off staff and mulling ...

Phio Pharmaceuticals Corp. PHIO shares are up on Tuesday’ as the company announced positive results from its Phase 1b clinical trial for its lead candidate, PH-762. The $9 million market cap biotech ...

-- Metastatic non-small cell lung cancer (NSCLC) patients treated in the first line setting with IO102-IO103 in combination with Keytruda® demonstrated promising activity with an overall response rate ...

Krystal Biotech (KRYS) stock gains as the company wins FDA RMAT designation for its lung cancer therapy KB707. Read more here ...

FDA decision puts pelareorep in focus Oncolytics Biotech (NasdaqCM:ONCY) is back on investor radars after the FDA granted Fast Track Designation to pelareorep in a combination regimen for second line ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

IO Biotech's co-founder presented advancements in cancer vaccines at the 2025 AACR Annual Meeting, highlighting innovative therapeutic strategies. IO Biotech, a clinical-stage biopharmaceutical ...

Phio Pharmaceuticals Corp. PHIO stock is trading lower on Thursday; however, there is no news to justify the movement. The stock could possibly be down on profit-taking after the stock closed nearly ...

Officials at Northway Biotech say they will leverage the company’s expertise to develop a robust manufacturing process for KAD101. This involves Northway’s developing and qualifying analytical methods ...

Johnson & Johnson plans to acquire clinical-stage biotech Halda Therapeutics OpCo. Inc. in a deal worth $3.05 billion. The New Brunswick-based pharma giant announced the agreement Nov. 17. The move ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...